[Structure-based drug development and medical/biological application of cathepsin specific inhibitors].
Katunuma
Nobuhiko
N
Institute for Health Sciences, Tokushima Bumi University, 180 Nishihamabouji, Yamashiro-cho, Tokushima City, Tokushima 770-8514, Japan.
D017951:Antigen Presentation; D001324:Autoantigens; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D002403:Cathepsins / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000502:physiology; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004852:Epoxy Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008247:Lysosomes; D010024:Osteoporosis; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use; D011487:Protein Conformation; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011736:Pyridoxine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011972:Receptor, Insulin / Q000378:metabolism; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000276:immunology
D001324:Autoantigens; C402823:CLIK 148; C406022:CLIK 164; D004151:Dipeptides; D004852:Epoxy Compounds; D011422:Propionates; D011725:Pyridines; C068249:N-(3-ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline; C068250:N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline; D011972:Receptor, Insulin; D002403:Cathepsins; D011736:Pyridoxine